The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).
Thomas Brodowicz
Honoraria - Amgen; Merck Serono
Damir Vrbanec
No relevant relationships to disclose
Klaus Kaczirek
Honoraria - Merck; Novartis; Roche
Research Funding - Covidien; Merck
Tudor-Eliade Ciuleanu
Consultant or Advisory Role - Amgen; Merck
Honoraria - Amgen; Merck
Regina Knittelfelder
No relevant relationships to disclose
Elisabeth Lindner
No relevant relationships to disclose
Diethelm Messinger
Employment or Leadership Position - IST GmbH
Christoph Zielinski
No relevant relationships to disclose
Berthold Streubel
No relevant relationships to disclose